| 17.59 0 (0%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is a biotechnology firm focused on the discovery, development, and commercialization of peptide-based medications. The company's therapeutic pipeline and marketed products primarily address gastrointestinal and metabolic diseases, as well as other niche conditions with significant unmet medical needs. Currently, Zealand Pharma markets lixisenatide under the brand names Adlyxin and Lyxumia. Its product portfolio also includes Dasiglucagon, offered as a single-use syringe or autoinjector for managing severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia, alongside its use in a dual-hormone artificial pancreas for automated diabetes care. In its advanced development stage, Dasiglucagon is progressing through Phase III clinical trials for congenital hyperinsulinism. Another significant late-stage asset is glepaglutide, a long-acting GLP-2 analogue, also in Phase III trials for the treatment of short bowel syndrome. Zealand Pharma A/S has established key collaboration agreements with entities such as Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Mon, 27 Jul 2026
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) - GlobeNewswire
Fri, 24 Jul 2026
Zealand Pharma A/S Revenue Breakdown – OMXCOP:ZEAL - TradingView
Wed, 08 Jul 2026
Zealand Pharma (CPSE:ZEAL) Stock Stays Reasonable On Earnings Yet Richer On Fair Value - Yahoo Finance
Tue, 30 Jun 2026
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 - Yahoo Finance
Sat, 27 Jun 2026
ZEAL Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|